secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADMA BIOLOGICS, INC. (ADMA)
CIK:        0001368514
Form:       8-K
Filed at:   2023-11-08T23:59:59+00:00
Accession:  0001140361-23-052102
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ADMA Biologics Q3 2023: first-time net income $2.6M, revenue $67.3M (+64% YoY), raises FY guidance
--------------------------------------------------------------------------------

- Total revenues $67.3M, up 64% YoY; first-time positive GAAP net income of $2.6M (vs $14.9M loss YoY).
- Adjusted EBITDA grew to $12.7M, up 98% QoQ; first-time positive operating cash flow of $12.0M; cash balance $74.2M.
- Gross margin improved to 36.6% from 23.5% YoY; net leverage ratio improved to 1.6x.
- FY2023 revenue guidance raised to >$250M; FY2024 >$290M; FY2025 >$335M (from $240M, $275M, $320M previously).
- Targets consolidated gross margin 40-50% and net income margin 20-30% in 2024-2025; ongoing strategic review.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1368514/000114036123052102/0001140361-23-052102-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1368514/000114036123052102/ef20014134_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-052102

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer